Company intelligence / Profile preview
City Therapeutics
Cambridge, Massachusetts, United Statescitytx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Company is in pre-clinical stage with first program expected to enter clinical development around the end of 2025. They have a strategic collaboration with Bausch + Lomb for an RNAi therapy for retinal diseases.
- Therapeutic areas
- OtherOphthalmology
- Modalities
- RNAi therapeuticssmall interfering RNAs (siRNAs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Bausch + Lomb (for retinal diseases including geographic atrophy)
Beyond the preview
Go deeper on City Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on City Therapeutics.